Composite Plot for Visualizing Aminotransferase and Bilirubin Changes in Clinical Trials of Subjects with Abnormal Baseline Values

• Published in: Drug safety Vol. 47; no. 7; pp. 699 - 710
• Main Authors: Tesfaldet, Bereket, Patel, Tejas, Chen, Minjun, Pucino, Frank, Rosario, Lilliam, Hayashi, Paul, Navarro Almario, Eileen
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.07.2024; Springer Nature B.V
• Subjects: Bilirubin; Clinical trials; Drug Safety and Pharmacovigilance; Gallbladder diseases; Health services; Hepatitis; Hepatotoxicity; Laboratories; Laboratory tests; Liver; Liver diseases; Medicine; Medicine & Public Health; Original; Original Research Article; Pharmacology/Toxicology; Visualization
• ISSN: 0114-5916; 1179-1942
• DOI: 10.1007/s40264-024-01425-5

Introduction On-treatment excursions of liver laboratory test values in clinical trials involving subjects with underlying liver disease are relevant for the efficacy and safety assessment of drug products and biologics. Existing visualization and analysis tools do not efficiently provide an integrated view of these excursions when baseline liver tests are abnormal. Objective The aim of this study was to develop a composite plot that enables visualization of on-treatment changes in liver test results both as multiples of the upper limit of normal defined by each laboratory’s reference population (×ULN) and multiples of the subjects’ baseline (×BLN) values. Methods The composite plot approach combines biochemical evaluation for drug-induced severe hepatotoxicity (eDISH) plots sequentially applied to subjects’ baseline and peak on-treatment liver test results normalized by ULN and integrates them into a four-panel shift plot of peak on-treatment values normalized by BLN. Results The composite plot enabled efficient assessment of improvement in liver test values during treatment compared with pretreatment in subjects treated with the investigational drug (or the natural history of placebo-treated subjects) and identified outlier subjects for potential drug-induced liver injury. Conclusion For studies in subjects with abnormal baseline values, the composite plot has potential application in the assessment of beneficial and concerning on-treatment modifications in liver test values in reference to the individual subject’s baseline and population threshold values.